 |
 |

Toxoplasmic Retinochoroiditis: A Double Blind Therapeutic Study
THOMAS E. ACERS, MD
Arch Ophthalmol. 1964;71(1):58-62.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
 |
 |
Introduction
The treatment of toxoplasmic retinochoroiditis has been the subject of numerous investigations over the past ten years. Therapeutic regimes seem to fall into four general groups: (1) watchful waiting, (2) corticosteroids, (3) pyrimethamine (Daraprim) and sulfonamides, with or without corticosteroids, and (4) antimicrobial agents such as spiramycin, chlortetracycline (Aureomycin), chloramphenicol (Chloromycetin), etc. Since the earliest studies of Sabin and Warner25 in 1942, in which the therapeutic effectiveness of sulfonamides in toxoplasmosis of mice and rabbits was demonstrated, extensive investigations have been made to find a more specific therapeutic agent effective against this organism.
In 1952, Eyles and Coleman6 initiated the first systematic survey of a number of compounds for antitoxoplasmic activity. These included the broad spectrum antibiotics, such as chloramphenicol, tetracyclines, neomycin, etc. The antitoxoplasmic activity of these compounds was slight and then only when used in extremely high doses.
In March of 1952, these authors reported
. . . [Full Text PDF of this Article]
Author Affiliations
Lawton, Okla
From the Wilmer Ophthalmological Institute of The Johns Hopkins Hospital, Baltimore 5, Md.
Footnotes
Submitted for publication June 27, 1963.
This study was supported by the Training Grant, No. 2B-5217, from the National Institute of Neurological Diseases and Blindness, US Public Health Service.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
|